Top Banner
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Narcotics, Narcotic Antagonists, and Antimigraine Agents Chapter 26
50
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotics, Narcotic Antagonists, and Antimigraine Agents

Narcotics, Narcotic Antagonists, and Antimigraine Agents

Chapter 26

Page 2: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

PainPain

• Definition

– Sensory and emotional experience associated with actual or potential tissue damage

• Drugs Used to Relieve Pain

– Narcotics: Opium derivatives used to treat many types of pain

– Antimigraine Drugs: Reserved for the treatment of migraine headaches

Page 3: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Neural Pathways of PainNeural Pathways of Pain

Page 4: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Gate-Control Theory of Pain Gate-Control Theory of Pain

• Sensory and emotional experience

• Transmission of these impulses can be modulated or adjusted

• Interneurons can act as “gates”

• Several factors, including learned experiences, cultural expectations, individual tolerance, and the placebo effect, can activate the descending inhibitory nerves from the upper central nervous system

Page 5: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Location of Opioid ReceptorsLocation of Opioid Receptors

• CNS

• Nerves in the periphery

• Cells in the gastrointestinal (GI) tract

Page 6: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic AgonistsNarcotic Agonists

• Actions

– Act at specific opioid receptor sites in the CNS

– Produce analgesia, sedation, and a sense of well-being

• Indications

– Relief of severe acute or chronic pain

– Analgesia during anesthesia

– Cross placenta

Page 7: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Agonists (cont.)Narcotic Agonists (cont.)

• Pharmacokinetics

– IV most reliable way to achieve therapeutic response

– IM and sub-q rate of absorption varies

– Hepatic metabolism and generally excreted in the urine and bile

• Contraindications

– Known allergy

– Pregnancy, labor, lactation

– Diarrhea caused by poisons

Page 8: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Agonists (cont.)Narcotic Agonists (cont.)

• Cautions

– Respiratory dysfunction

– GI or GU surgery

– Acute abdomen or ulcerative colitis

• Adverse Reactions

– Respiratory depression with apnea

– Cardiac arrest

Page 9: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Agonists (cont.)Narcotic Agonists (cont.)• Adverse Reactions (cont.)

– Shock

– Orthostatic hypotension

– Nausea, vomiting, constipation

– Biliary spasm

– Dizziness, psychoses, anxiety, fear, hallucinations

• Drug-to-Drug Interactions

– Barbiturate general anesthetics, phenothiazines, and MAOIs

Page 10: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

Identify a reason a narcotic agonist may be prescribed?

A. Relief of minor pain

B. Analgesia during anesthesia

C. Analgesia during sleep

D. Relief of moderate acute pain

Page 11: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

b. Analgesia during anesthesia

Rationale: Indications:

– Relief of severe acute or chronic pain

– Analgesia during anesthesia

– Cross placenta

Page 12: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Agonists–AntagonistsNarcotic Agonists–Antagonists

• Buprenorphine (Buprenex)

– Treats mild to moderate pain

• Butorphanol (Stadol, Stadol NS)

– Preoperative medication

– Relieves moderate to severe pain

• Nalbuphine (Nubain)

– Treats moderate to severe pain

– Adjunct for general anesthesia

– Relieves pain during labor and delivery

Page 13: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Agonists–Antagonists (cont.)Narcotic Agonists–Antagonists (cont.)

• Pentazocine (Talwin)

– Preferred drug for patients switched from parenteral to oral forms after surgery or labor

Page 14: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Agonists–Antagonists (cont.)Narcotic Agonists–Antagonists (cont.)

• Actions

– Act at a specific opioid receptor sites in the CNS to produce analgesia, sedation, euphoria, and hallucinations

• Indications

– Moderate to severe pain

– Adjunct to general anesthesia

– Relief of pain during labor and delivery

Page 15: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Agonists–Antagonists (cont.)Narcotic Agonists–Antagonists (cont.)

• Pharmacokinetics

– Readily absorbed IM and reach peak levels when given IV

– Metabolized in the liver excreted in urine or feces

– Cross placenta

• Contraindications

– Known allergy

– Pregnancy and lactation

Page 16: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Agonists–Antagonists (cont.)Narcotic Agonists–Antagonists (cont.)

• Cautions

– Physical dependence on a narcotic

– COPD and disease of the respiratory tract

– Acute MI or documented CAD

• Adverse Reactions

– Respiratory depression

– Nausea, vomiting, constipation, and biliary spasm

Page 17: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Agonists–Antagonists (cont.)Narcotic Agonists–Antagonists (cont.)

• Adverse Reactions

– Headache

– Dizziness

– Psychoses

– Anxiety

– Hallucinations

– Ureteral spasm, urinary retention

• Drug-to-Drug Interactions

– Barbiturate general anesthetics

Page 18: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic AntagonistsNarcotic Antagonists

• Nalmefene (Revex)

– Reverses the effects of narcotics; manages known or suspected narcotic overdose

• Naloxone (Narcan)

– Reverses adverse effects of narcotics; diagnoses suspected acute narcotic overdose

• Naltrexone (ReVia)

– Used orally in the management of alcohol or narcotic dependence

Page 19: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Antagonists (cont.)Narcotic Antagonists (cont.)

• Actions

– Drugs that bind strongly to opioid receptors, but they do not activate the receptors

– Reverse effects of opioids

• Indications

– Reversal of the adverse effects of narcotics

– Treat narcotic and/or alcoholic dependence

Page 20: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Antagonists (cont.)Narcotic Antagonists (cont.)

• Pharmacokinetics

– Well absorbed after injection and are widely distributed in the body

– Hepatic metabolism and excreted in the urine

– Enter breast milk

• Contraindications

– Known allergy

Page 21: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Antagonists (cont.)Narcotic Antagonists (cont.)

• Adverse Reactions

– Tachycardia

– Blood pressure changes

– Dysrhythmias

Page 22: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Narcotic Antagonists (cont.)Narcotic Antagonists (cont.)

• Drug-to-Drug Interactions

– Reverse Effects on:

• Buprenorphine

• Butorphanol

• Nalbuphine

• Pentazocine

• Propoxyphene

Page 23: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

Identify one indicator for a narcotic antagonist to be prescribed?

A. Treatment of alcohol independence

B. Reversal of bronchoconstriction

C. Treatment of narcotic dependence

D. Reversal of tachycardia

Page 24: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

C. Treatment of narcotic dependence

Rationale: Indications

– Reversal of the adverse effects of narcotics

– Treat narcotic and/or alcoholic dependence

Page 25: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

HeadachesHeadaches

• Migraine Headaches

– Severe, throbbing headaches on one side of the head

• Cluster Headaches

– Begin during sleep; involve sharp, steady eye pain, sweating, flushing, tearing, and nasal congestion

• Tension Headaches

– Usually occur at times of stress; dull band of pain around the entire head

Page 26: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Ergot DerivativesErgot Derivatives

• Actions

– Block alpha-adrenergic and serotonin receptor sites in the brain to cause constriction of cranial vessels

• Indications

– Prevention or abortion or migraine or vascular headaches

Page 27: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Ergot Derivatives (cont.)Ergot Derivatives (cont.)

• Pharmacokinetics

– Rapidly absorbed from many routes

– Onset of action range from 15-30 minutes

– Metabolized in the liver and primarily excreted in the bile

– Excreted in breast milk

Page 28: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Ergot Derivatives (cont.)Ergot Derivatives (cont.)

• Contraindications

– Known allergy

– Pregnancy or lactation

– CAD

– HTN

– PVD

• Cautions

– Pruitus

– Malnutrition

Page 29: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Ergot Derivatives (cont.)Ergot Derivatives (cont.)• Adverse Reactions

– Numbness

– Tingling of extremities

– Muscle pain

– Pulselessness

– Weakness

– Chest pain

– Arrhythmias

– Nausea

– Vomiting

– Diarrhea

Page 30: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Ergot Derivatives (cont.)Ergot Derivatives (cont.)

• Drug-to-Drug Interactions

– Beta blockers

Page 31: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

TriptansTriptans

• Actions

– Bind to selective serotonin receptors sites to cause vasoconstriction of cranial vessels

• Indications

– Treatment of acute migraine and are not used for prevention of migraines

Page 32: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Triptans (cont.)Triptans (cont.)

• Pharmacokinetics

– Rapidly absorbed from many sites

– Metabolized in the liver

– Primarily excreted in the urine

– Cross the placenta and enter breast milk

• Contraindications

– Known allergy, pregnancy, CAD

Page 33: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Triptans (cont.)Triptans (cont.)

• Cautions

– Elderly, risk factors for CAD, and lactation

• Adverse Reactions

– Numbness, tingling, burning sensation, feeling of coldness, weakness, dysphasia, blood pressure alterations

• Drug-to-Drug Interactions

– Ergot – containing drugs

– MAOI’s

Page 34: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Use of Narcotics and Antimigraine Agents Across the Lifespan

Use of Narcotics and Antimigraine Agents Across the Lifespan

Page 35: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Narcotic AgonistsPrototype Narcotic Agonists

Page 36: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Narcotic Agonists–Antagonists Prototype Narcotic Agonists–Antagonists

Page 37: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Narcotic AntagonistsPrototype Narcotic Antagonists

Page 38: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Narcotic Antagonists (Continued)

Prototype Narcotic Antagonists (Continued)

Page 39: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Ergot DerivativesPrototype Ergot Derivatives

Page 40: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Ergot Derivatives (Continued)Prototype Ergot Derivatives (Continued)

Page 41: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype TriptansPrototype Triptans

Page 42: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

What is an action of Ergotamine?

A. Decreases hyperfusion of basilar artery vascular bed

B. Increases hyperfusion of basilar artery vascular bed

C. Increases hypoperfusion of basilar artery vascular bed

D. Decreases hypoperfusion of basilar artery vascular bed

Page 43: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

A. Decreases hyperfusion of basilar artery vascular bed

Rationale: Actions: Constricts cranial blood vessels, decreases pulsation of cranial arteries, and decreases hyperfusion of basilar artery vascular bed; mechanism of action is not understood

Page 44: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Considerations for Narcotic AgonistsNursing Considerations for Narcotic Agonists

• Assessment: History and Physical Exam

• Nursing Diagnosis

• Implementation

• Evaluation

Page 45: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Considerations for Narcotic Agonists–Antagonists

Nursing Considerations for Narcotic Agonists–Antagonists

• Assessment: History and Physical Exam

• Nursing Diagnosis

• Implementation

• Evaluation

Page 46: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Considerations for Narcotic AntagonistsNursing Considerations for Narcotic Antagonists

• Assessment: History and Physical Exam

• Nursing Diagnosis

• Implementation

• Evaluation

Page 47: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Considerations for Ergot DerivativesNursing Considerations for Ergot Derivatives

• Assessment: History and Physical Exam

• Nursing Diagnosis

• Implementation

• Evaluation

Page 48: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Considerations for TriptansNursing Considerations for Triptans

• Assessment: History and Physical Exam

• Nursing Diagnosis

• Implementation

• Evaluation

Page 49: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

The nurse is caring for a patient with Parkinson’s disease. While writing the care plan for this patient what would be an appropriate nursing diagnosis?

A. Constipation related to dopaminergic effects

B. Diarrhea related to dopaminergic effects

C. Risk for injury related to CVS effects and incidence of orthostatic hypotension

D. Risk for injury related to CVS effects and incidence of PVD

Page 50: Ppt chapter 26-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

A. Constipation related to dopaminergic effects

Rationale: Nursing diagnoses related to drug therapy might include: Constipation related to dopaminergic effects; Risk for injury related to CNS effects and incidence of orthostatic hypertension